Clinical study

Intracranial meningioma and breast cancer

Ann-Shung Lieu, Shih-Lin Hwang, Shen-Long Howng

Department of Neurosurgery, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan

Summary Breast carcinoma has a high predisposition to metastasize to the brain parenchyma. An association between carcinoma of the breast and intracranial meningioma has been reported. The available published articles regarding patients with intracranial meningioma and breast carcinoma have been reviewed. To the best of our knowledge, 86 cases including our 4 cases have so far been reported. All cases were female, and the mean age was 62.4 years when intracranial meningioma was diagnosed. The mean interval of the 2 tumours was 4.5 years. Twenty-five cases of breast tumour were infiltrating duct carcinomas. The location of intracranial meningioma and pathologic subtype showed no specific predominance. Hormone receptor study was performed in 28 cases. In meningioma, the positive rate of progesterone receptor (32.1%) is higher than oestrogen receptor (7.1%); while the positive rate of oestrogen receptor (53.6%) is higher than the progesterone receptor (42.9%) in breast cancer. A review of this study is presented with emphasis on the existence of intracranial meningioma and breast cancer in one patient at different periods. Lesions of the central nervous system in patients with breast cancer should not be immediately labeled as metastases. Intracranial meningioma should be excluded. Likewise, patients with meningioma should have periodic physical examinations and mammographies whereby disease may be diagnosed and treated at an early stage.

Keywords: intracranial meningioma, breast cancer

INTRODUCTION

Breast carcinoma is considered a common malignant neoplasm in women. Patients with a history of breast carcinoma develop neurological symptoms and signs. Frequently, they are considered to have brain metastases and submitted to radiotherapy, quite often without any further investigation. However, multiple primary tumours, benign or malignant, coexisting in the same patient occur with a frequency of 2.8% in patients with neoplasms. ¹⁻³ Meningiomas represent 20% of all central nervous system tumours and are encountered twice as often in women as in men. ⁴

The existence of breast carcinoma and meningioma was suggested by Schoenberg et al. in 1975.⁵ An awareness of this existence, with modern techniques of investigation, may permit more cases to be diagnosed and treated earlier. Herein, we present 4 cases of intracranial meningioma and breast carcinoma, and a comprehensive review of the subject.

MATERIALS AND METHODS

During the period from January 1986 to May 1999, there were 4 cases of intracranial meningioma associated with breast carcinoma, out of a series of 246 intracranial meningiomas operated on at the Kaohsiung Medical University.

Case 1

A 40 year old woman underwent a left modified radical mastectomy in February 1996 for carcinoma of breast. Hormonal receptor studies were positive for estrogen and progesterone receptors. Following surgery, the patient received adjuvant chemotherapy and radiotherapy. In October 1998, she was read-

Received 30 July 2002 Accepted 31 October 2002

Correspondence to: Shen-Long Howng MD PhD, Department of Neurosurgery, Kaohsiung Medical University Hospital, No. 100, Shih-Chuan 1st Road, Kaohsiung City 807, Taiwan. Tel.: +886-7-3215049; Fax: +886-7-3215039.

mitted for progressive dizziness and vomiting. Brain computed tomography (CT) without contrast medium enhancement showed one isodense mass with calcification in the cerebellopontine angle. Infusion of contrast medium, revealed homogenous enhancement. Brain magnetic resonance imaging was performed which raised suspicion of a meningioma. Craniectomy was performed with total removal of the tumour, which was subsequently reported as psammomatous type of meningioma by pathologic studies. Oestrogen and progesterone receptor study were negative.

Case 2

This 60 year old women was admitted to our hospital in May 1996, complaining of progressive weakness in her left limbs and unstable gait. Ten years prior, she underwent a left mastectomy for carcinoma of the breast. During hospitalization, brain CT scans demonstrated a well-defined mass in the right temporal region with moderate perifocal oedema. After contrast medium, it revealed homogenous enhancement. Craniotomy with total removal of tumour was performed. Histopathologic examination revealed it to be meningotheliomatous type. Oestrogen and progesterone receptor assay was done. The results showed a positive response of progesterone; and, negative of oestrogen.

Case 3

This 42 year old woman suffered from focal seizure of right lower limb. Brain CT scans showed a well-defined mass in the left parietal region with severe perifocal oedema and focal calcification. Homogenous enhancement was noted after infusion of contrast medium. A craniotomy was performed with total removal of a falx meningioma. The pathologic study demonstrated a meningiotheliomatous meningioma. Progesterone receptor test was positive, and the estrogen receptor was negative. Four years and 5 months later, she was found to have a hard mass in the left breast. Biopsy showed infiltrating duct carcinoma. A modified radical mastectomy was done and negative nodes were found. She is doing well 13 years after craniotomy.

Case 4

A 46 year old woman with a mass in the left breast had a modified radical mastectomy after biopsy, showing infiltrating ductal carcinoma. All nodes were negative. Eight years later, she began exhibiting poor memory and bizarre behavior which was reported by her family. Brain CT scans showed a huge mass with perifocal oedema in the left frontal region. After infusion of contrast medium, it showed homogenous enhancement. Bone window showed left frontal hyperostosis. A craniotomy was performed with total excision of the tumour. Pathologic examination demonstrated a meningiotheliomatous meningioma. Oestrogen and progesterone receptor assay showed negative study. She had an uneventful postoperative recovery.

DISCUSSION

Between January 1986 and May 1999, 1853 patients with breast cancer underwent surgery in Kaohsiung Medical University. During this period, 246 patients underwent surgery for intracranial meningioma, giving a 1 to 7.5 ratio between intracranial meningioma and breast cancer, which is a considerably higher rate than that reported by Burns et al.⁶ and Smith et al.⁷ The interest in the existence of both breast cancer and meningioma is raised by the clinical relevance of an intracranial tumour discovered in a patient with history of breast cancer and the need to differentiate it from a metastasis.^{8,9,10}

Published articles were reviewed and they revealed 82 case reports of patients with both breast cancer and meningioma, to which we have added 4 cases. The clinical details of these are

Table 1 Clinical data of patients with breast cancer and meningiomas: Literature Review

Authors	Age at diagnosis of meningioma (years)	Site meningioma	Breast cancer type	Meningioma type	Interval between tumours (years)
Markopoulos et al.11	45 (1)	Convexity	NC	NC	0.8
Salvati ¹²	52.8*(9)	Convexity (3) Sphenoid ridge (6)	All IDC	Transitional (5) Psammomatous (2) Meningotheliomatous(2)	4.1*
Cervoni et al.13	65 (1)	Falx	ILC	Fibroblastic	<0.1
Di Bonito et al. ⁸	74.9* (12)	Vault (6) Convexity (2) Parasellar (1)	IDC (9) ILC (2) NC (1)	Psammomatous (7) Transitional (4) Meningotheliomatous (1)	Unknown
		Middle fossa (1)			
Smith-Behn ¹⁴		Unknown (2)			
	68.8* (4)	Olfactory (1) Unknown (3)	IDC (3) NC(1)	NC (4)	3.6*
Chow et al.15	50 (1)	Sphenoid ridge	NC	Meningotheliomatous	8
Knuckey et al. ¹⁶	63.2* (5)	Convexity (2) Parasagittal (1) Posterior fossa (1) Middle fossa (1)	NC (5)	Fibroblastic (3) Psammomatous (1) Meningotheliomatous (1)	5.8*
Rubinstein et al. ⁹	61.2* (9)	Convexity (5) Multiple (2) Suprasellar (1)	NC (9)	NC (9)	4.1*
	(.)	Parasagittal (1)			_
Zon et al. ¹⁷	63 (1)	Convexity	ILC	NC	6
Doron ³	64 (1)	Convexity	NC NC	Meningotheliomatous NC	3
Jacob et al. ¹⁸	68.6* (12)	Sphenoid ridge (5) Unknown (7)	NC		11.4*
Burns et al.6	56.4* (5)	Convexity (2)	IDC (2)	Meningiotheliomatous (2)	6.2*
		Suprasellar (1) Sphenoid ridge (1) Unknown (1)	NC (2) Other (1)	Mixed (2) NC (1)	
Mehta et al. ¹⁰	70* (3)	Olfactory (1) Posterior fossa (1) Falx (1)	NC (3)	NC (3)	2.2*
Barz ¹⁹	56 (1)	Unknown	NC	Meningotheliomatous	2
_odrini ²⁰	54 (1)	Olfactory	NC	Meningotheliomatous	1.2*
Chamber et al.21	66 (1)	Unknown	NC	Psammomatous	_
Savoiardo ²²	53 (1)	Olfactory	NC	Meningotheliomatous	1
Pöyhönen et al. ²³	79 (1)	Convexity	NC	Meningotheliomatous	2
Smith ⁷	55* (2)	Parasagittal (1) Convexity (1)	IDC (2)	NC (2)	5.8*
Kepes ²⁴	52 (1)	Convexity	NC	Meningotheliomatous	2.5
Schoenberg et al. ⁵	63.3* (7)	Unknown	NC (7)	NC (7)	7*
Haar ²⁵	Middle (1)	Convexity	NC	NC	2
Γheologides ²⁶ Anlyan et al. ²⁷	74 (1) 42 (1)	Convexity	Scirrhous	Meningotheliomatous	0.2
Raskind ²⁸	57 (1)	Sphenoid ridge	NC	NC	7.2
Kubo et al.40	57 (1)	Parasagittal	IDC	Transitional	4
Present	49.5* (4)	Convexity (2) Falx (1) Posterior fossa (1)	IDC (3) Carcinoma (1)	Meningotheliomatous (3) Psammomatous (1)	6.3*

^{*} Mean

IDC, infiltrating ductal carcinoma; ILC, infiltrating lobular carcinoma; NC, no classification; (), in authors' line, it represents reference number, the others represent case number.

Table 2 Differential diagnosis of intracranial meningioma from metastatic breast carcinoma

	Intracranial meningioma	Metastasis	
Skull X-ray	Hyperostosis	Destruction	
СТ			
Non-enhanced	Isodense or slightly hyperdense	Variable	
Enhanced	Well-defined mass with homogenous enhancement	Well-defined mass with heterogenous enhancement and extensive perifocal oedema	
MRI			
Non-enhanced	T1-weighted: isointense or mildly hypointense	T1-weighted: hypointense	
	T2-weighted: isointense or mildly hyperintensive	T2-weighted: hyperintense	
Enhanced	Homogenous enhancement with meningeal tail	Heterogenous enhancement	

summarised in Table 1. The mean age of presentation for patients with intracranial meningioma was 62.4 years, and mean age for patients with breast cancer was 56.2 years. This age is typical of patients with either intracranial meningioma or breast cancer. Breast cancer was diagnosed first in 80.2% of cases and the mean duration before the diagnosis of the second tumour, be it breast cancer or intracranial meningioma, was 4.5 years. The longest interval between tumour diagnoses was 29 years.¹⁸ The trend of breast cancer presentation first, which is also reflected in 3 of our 4 patients, may simply reflect the slow growth of intracranial meningioma. The location of intracranial meningioma was as follows: convexity (23 cases), sphenoid ridge (15), parasagittal/ falx (7), olfactory (4), others (18) and unknown (21). The subtype of meningioma was as follows: meningotheliomatous (17), psammomatous (12), transitional (10), fibroblastic (5), mixed (2) and no classification (40). The location and subtype of intracranial meningioma revealed no specific predominance.

Breast cancer and meningioma share several features that might account for their existence in 1 patient. From epidemiologic survey, both tumours occur commonly in the same adult female population, usually in the fifth and sixth decade; which is similar to those in our review. 4,29 From the viewpoint of clinical course, intracranial meningioma express symptoms rapidly, with an increase in size during pregnancy and a complete clinical subsidence postpartum.30,31 It has yet to be clarified as to whether the increase in size is due to an expedition of the rate of growth, influenced by hormonal changes during pregnancy, or to an increased fluid content, based on the generally increased water retention during pregnancy.5,11,30,31

Breast cancer cells often express oestrogen and progesterone receptors.³² In meningioma, oestrogen receptors had been detected initially, but progesterone receptors were later documented in higher tissue concentration.^{33–35} In fact, quantitative assessment of these hormone receptors usually yielded twice as many progesterone receptors as oestrogen receptors in meningiomas. 34,36 In breast cancer, the cytoplasmic progesterone receptors are usually elevated when cytoplasmic oestrogen receptors are present in high levels.¹⁷ Therefore, the hormone receptor status of meningioma appears to be different from that of breast cancer. This discrepancy suggests a possible derangement of the normal cellular hormonal control mechanism in meningioma.¹⁷ In our 4 meningioma cases, progesterone receptor tests were positive in 2 patients, and oestrogen receptor tests were all negative. Among the 86 reviewed cases, including our 4 cases, hormone receptor tests were performed in 28 cases. Regarding intracranial meningioma, the progesterone receptor tests were positive in 9 cases (32.1%), and oestrogen receptor tests were positive in only 2 cases (7.1%). This incidence is similar to the report of Cahill et al.,³⁴ but is lower than other authors' reports. 35-38 In breast cancer, oestrogen receptor positive rate (53.6%) is higher than the progesterone receptor rate (42.9%), but is of no significant difference.

Jacobs et al.¹⁸ and Salvati et al.¹² suggested sphenoidal ridge meningiomas were more likely to be associated with breast cancer. However, in our study the association was not apparent.

Onset and types of neurologic symptoms and signs can not be used to distinguish between metastatic breast cancer and intracranial meningioma, since they are similar. Brain CT scans and magnetic resonance imaging (MRI) may be useful (Table 2). On brain CT scans and MRI, metastasis of the breast cancer shows as outward expansion of the gray/white matter junction (intra-axial lesion) rather than inward buckling by the intracranial meningioma (extra-axial lesion). Extensive perifocal oedema is present with metastasis, whereas this is not common in intracranial meningioma. Bone destruction is found in metastasis, but in intracranial meningioma, hyperostosis may be seen. On enhanced MRI, intracranial meningiomas undergo homogenous enhancement with linear enhancement along the dura adjacent to the tumour (meningeal "tail").39

In summary, intracranial meningioma and breast cancer usually occur in the same age groups; therefore, the physician should be aware of the possibility of the existence of both breast cancer and intracranial meningioma. The findings of cerebral mass in a patient with breast cancer should not definitively indicate metastasis. Resectable intracranial meningioma should be diagnosed differentially. Likewise, patients with intracranial meningioma should have periodic physical examinations and mammographies, by which disease may be diagnosed and treated at an early stage.

REFERENCES

- Moetrel CG. Incidence and significance of multiple primary neoplasms. Ann N Y Acad Sci 1961: 114: 886-895.
- Lodrini S, Savoiardo M, Metastases of carcinoma to intracranial meningioma: report of two cases and review of the literature. Cancer 1981; 48: 2668-2673.
- Doron Y, Gruskiewicz J. Metastasis of invasive carcinoma of the breast to an extradural meningioma of the cranial vault. Cancer 1987; 60: 1081-1084.
- Al-Mefty O. Meningiomas, first edn. Raven Press Ltd., New York; 1991: 27 - 35
- Schoenberg BS, Christine BW, Whisnant JP. Nervous system neoplasms and primary malignancies of other sides. The unique association between meningioma and breast cancer. Neurology 1975; 25: 705-712.
- Burns PE, Naresh J, Bain GO. Association of breast cancer with meningioma: a report of five cases. Cancer 1986; 58: 1537-1539.
- Smith FP, Slavik M, MacDonald JS. Association of breast cancer with meningioma: report of two cases and review of the literature. Cancer 1978; 42: 1992-1994.
- Di Bonito L, Giarelli G, falconieri D, Bonifacio-Gori G, Vielh P. Association of breast cancer and meningioma: report of 12 new cases and review of the literature. Path Res Pract 1993; 189: 399-404.
- Rubinstein AB, Schein M, Reichenthal E. The association of carcinoma of the breast with meningioma. Surg Gynecol Obstet 1989; 169: 334-336.
- Metha D, Khatib R, Patel S. Carcinoma of the breast and meningioma Association of Management. Cancer 1983; 51: 1937-1940.
- Markopoulos C, Sampalis F, Givalos N, Gogas H. Association of breast cancer with meningioma. Eur J Surg Oncol 1998; 24: 332-334.

- Salvati M, Cervoni L. Association of breast carcinoma and meningioma: report of nine new cases and review of the literature. Tumori 1996; 82: 491–493.
- Cervoni L, Salvati M, Gagliardi D, Delfini R. Metastasis of breast carcinoma to intracranial meningioma. Case report. Neurosurg Rev 1994; 17: 233–236.
- Smith-Behn J. Relationship between breast cancer and meningioma. South Med J 1992; 85: 146–147.
- Chow WC, Ho KH, Fong CM. Intracranial meningioma with metastatic breast carcinoma. Ann Oncol 1992; 3: 409–410.
- Knuckey NW, Stoll J, Epstein MH. Intracranial and spinal meningiomas in patients with breast cancinoma: case reports. Neurosurgery 1989; 25: 112–117.
- Zon LI, Johns WD, Stomper PC, Kaplan WD, Connolly JL, Morris JH et al. Breast carcinoma metastatic to a meningioma. Arch Intern Med 1989; 149: 950-962
- Jacobs DH, McFarlane MJ, Holmes FF. Female patients with meningioma of the sphenoid ridge and additional primary neoplasms of the breast and genital tract. Cancer 1987; 60: 3080–3082.
- Barz H. The incidence of metastatic carcinomas in meningiomas. Ebl Allg Pathol 1983; 127: 367–374.
- Lodrini S, Savoiardo M. Metastases of carcinoma to intracranial meningioma: report of two cases and review of the literature. Cancer 1981; 48: 2668–2673.
- Chamber PW, Davis RL, Buck FS. Metastases to primary intracranial meningiomas and neurilemomas. Arch Path Lab Med 1980; 104: 350–354.
- Savoiardo M, Lodrini S. Hypodense area within a meningioma: metastasis from breast cancer. Neuroradiology 1980; 20: 107–110.
- Pöyhönen L, Heikkinen J, Vehkalahti I. Two different primary tumors of the brain in a patient with breast cancer. Eur J Nucl Med 1979; 4: 483–484.
- Kepes JJ. Cellular whorls in brain tumors other than meningiomas. Cancer 1976; 37: 2232–2237.
- Haar F, Patterson RH. Surgery for metastatic intracranial neoplasm. Cancer 1972; 30: 1241–1245
- 26. Theologides A, Lee JC. Tumor to tumor metastasis. JAMA 1972; 219: 384.
- 27. Anlyan F, Heinzen BR, Carras R. Metastasis of tumor to second different tumors: collision tumors. JAMA 1970; 212: 2124.

- Raskind R, Weiss SR. Conditions simulating metastatic lesions of the brain. Report of eight cases. Int Surg 1970; 53: 40–43.
- Barber H. Manual of Gynecologic Oncology. JB Lippincott, Philadephia; 1989. Codio: 12, 491/abbi, 1996.
- Michelsen JJ, New PFJ. Brain tumor and pregnancy. J Neurol Neurosurg Psychiat 1969; 32: 305–307.
- Bickerstaff ER, Small JM, Guest IA. The relapsing course of certain meningiomas in relation to pregnancy and menstruation. J Neurol Neurosurg Psychiat 1958; 21: 89–91.
- Osborne CK, Yochmowitz MG, Knight III WA, McGuire WL. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 1980; 46(suppl 12): 2884–2888.
- Donnell MS, Meyer GA, Donegan WL. Estrogen receptor protein in intracranial meningiomas. J Neurosurg 1979; 50: 499–502.
- Cahill DW, Bashirelahi N, Solomon LW, Dalton T, Salcman M, Ducher TB. Estrogen and progesterone receptors in meningiomas. J Neurosurg 1984; 60: 985–993.
- Martuza RL, Miller DC, MacLaughlin DT. Estrogen and progestin binding by cytosolic and nuclear fractions of human meningiomas. J Neurosurg 1985; 62: 750–756.
- Schwartz MR, Randoph RL, Cech DA, Rose JE, Panko WB. Steroid hormone binding macromolecules in meningiomas. Failure to meet criteria of specific receptors. Cancer 1984; 53: 922–927.
- Poisson M, Magdelenant H, Foncin JF, Bleibel JM, Philippon J, Pertuiset B et al. Récepteurs Dóestrogéne et de progésterone dans les meningiomas. Etude de 22 cas. Rev Neurol 1980: 136: 193–203.
- Maiuri F, Montagnani S, Gallicchis B. Estrogen and progesterone receptors in meningiomas. Surg Neurol 1986; 26: 430–435.
- Goldsher D, Litt AW, Pinto RS, Bannon KR, Kricheff II. Dural "tail" associated with meningiomas on Gd-DTPA-enhanced MR images: characteristics, differential diagnostic value, and possible implications for treatment. Radiology 1990; 176: 447–450.
- Kubo M, Fukutomi T, Akashi-Tanaka S, Hasegawa T. Association of breast cancer with meningioma: report of a case and review of the literature. Jpn J Clin Oncol 2001; 31: 510–513.